Freenome Scores $160M In New Funding. So What's Next?
With Freenome recently scoring $160m in new financing, the San Francisco-based start-up is poised to ramp up development of its cancer-detection platform. Medtech Insight hears from the firm's CEO and co-founder, Gabe Otte, about the company's next steps.
You may also be interested in...
Funding will accelerate an FDA registrational study of the company's first liquid biopsy product, as competition increases in early cancer detection.
Device financing increased substantially in Q3, thanks to debt raises led by Insulet. Acquisition dollar volume dropped, though, but Siemens' buy of Corindus for $1.1bn was a stand-out. Diagnostics/research tools financing dropped by 28% from Q2, while acquisition value greatly increased due to Exact Sciences' $2.8bn purchase of Genomic Health.
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.